A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, PA / ACCESS ...
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 ...
Medicus Pharma Ltd ( (MDCX)) has shared an announcement. Medicus Pharma has released an interpretation of Phase 2 data for its SkinJect microneedle delivery system in basal cell carcinoma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results